Peptide LibraryCetrorelix dosage in published studies and labels
These are the doses used for Cetrorelix in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Cetrorelix has an FDA-approved human dosage for preventing a premature LH surge in women having controlled ovarian stimulation. The Cetrotide label dose is 0.25 mg under the skin once a day, started on stimulation day 5 or 6 and continued until the day of hCG.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 0.25 mg once daily during ovarian stimulation, until the day of hCG |
| Route | Subcutaneous |
| Frequency | Once daily |
| Duration studied | From stimulation day 5 or 6 until the day of hCG |
| Evidence level | FDA Approved |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| FDA label — Cetrotide 0.25 mgFDA-approved label · FDA prescribing information | Women undergoing controlled ovarian stimulation | 0.25 mg | Subcutaneous | Once daily | From stimulation day 5 (morning or evening) or day 6 (morning) until the day of hCG administration | Inhibition of premature LH surges | CETROTIDE (cetrorelix acetate for injection) 0.25 mg — FDA prescribing information (EMD Serono), DailyMed |
| Cetrotide confirmatory trial (Mettler and Brandenburg, 2000)Clinical trial · Single-arm clinical trial | Women having ovarian stimulation with recombinant FSH for IVF or ICSI (n=26) | 0.25 mg | Subcutaneous | Once daily from cycle day 7 until the day of hCG | One stimulation cycle | Mean 5.5 oocytes retrieved in 24 patients; pregnancy in 10 patients | Mettler L, Brandenburg K. Cetrotide confirmatory trial of cetrorelix/0.25 mg in 26 women undergoing ovarian stimulation with recombinant follicle stimulating hormones for IVF, ICSI and embryo transfer (ET). Clin Exp Obstet Gynecol. 2000. |
Where sources disagree
- The Cetrotide label's clinical studies section also describes a single 3 mg dose regimen that was tested in phase 3, but its dosage section gives only the 0.25 mg daily regimen.
- Cetrorelix is one part of an IVF protocol: the label pairs it with gonadotropins from cycle day 2 or 3 and hCG to induce ovulation, and says no hCG should be given if the ovaries respond excessively.
- The label says pregnancy must be excluded before treatment and reports hypersensitivity reactions, including anaphylactoid reactions with the first dose.